WallStreetZenWallStreetZen

NASDAQ: JAZZ
Jazz Pharmaceuticals PLC Earnings & Revenue

JAZZ past earnings growth

How has JAZZ's earnings growth performed historically?
Company
N/A
Industry
50.74%
Market
104.8%
JAZZ's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
JAZZ's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance

JAZZ past revenue growth

How has JAZZ's revenue growth performed historically?
Company
4.78%
Industry
192.99%
Market
18.52%
JAZZ's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
JAZZ's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
JAZZ's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

JAZZ earnings and revenue history

Current Revenue
$3.8B
Current Earnings
$414.8M
Current Profit Margin
10.8%
JAZZ's has not demonstrated consistent... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

JAZZ Return on Equity

Current Company
11.8%
Current Industry
-64.7%
Current Market
188%
JAZZ's Return on Equity (11.8%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when JAZZ announces earnings.

JAZZ Return on Assets

Current Company
3.7%
Current Industry
6.6%
JAZZ is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

JAZZ Return on Capital Employed

Current Company
5.93%
Current Industry
23.6%
JAZZ's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

JAZZ vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
JAZZ$3.83B$1.22B$414.83M+15.19%-2.54%
CERE$0.00-$416.15M-$432.84MN/AN/A
CYTK$7.53M-$486.05M-$526.24M-24.89%N/A
APLS$396.59M-$495.21M-$528.63M+83.50%N/A
PCVX$0.00-$392.10M-$402.27MN/AN/A

Jazz Pharmaceuticals Earnings & Revenue FAQ

What were JAZZ's earnings last quarter?

On Invalid Date, Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 2023 earnings per share (EPS) of $1.50, up 138.96% year over year. Total Jazz Pharmaceuticals earnings for the quarter were $94.15 million. In the same quarter last year, Jazz Pharmaceuticals's earnings per share (EPS) was -$3.85.

If you're new to stock investing, here's how to buy Jazz Pharmaceuticals stock.

What was JAZZ's earnings growth in the past year?

As of Q1 2024, Jazz Pharmaceuticals's earnings has grown year over year. Jazz Pharmaceuticals's earnings in the past year totalled $414.83 million.

What was JAZZ's revenue last quarter?

On Invalid Date, Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 2023 revenue of $1.01 billion up 4.1% year over year. In the same quarter last year, Jazz Pharmaceuticals's revenue was $972.12 million.

What was JAZZ's revenue growth in the past year?

As of Q1 2024, Jazz Pharmaceuticals's revenue has grown 4.78% year over year. This is 188.21 percentage points lower than the US Biotechnology industry revenue growth rate of 192.99%. Jazz Pharmaceuticals's revenue in the past year totalled $3.83 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.